Captrust Financial Advisors Bristol Myers Squibb CO Transaction History

Captrust Financial Advisors

$30.9 Billion
Q2 2024

A detailed history of Captrust Financial Advisors transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Captrust Financial Advisors holds 412,972 shares of BMY stock, worth $20.4 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

412,972

Previous 448,729 7.97%

Holding current value

$20.4 Million

Previous $24.3 Million 29.52%

% of portfolio

0.06%

Previous 0.08%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$40.25 - $52.99 $1.44 Million - $1.89 Million	-35,757 Reduced 7.97%	412,972 $17.2 Million
Q1 2024 May 15, 2024	SELL	$47.98 - $54.4 $3 Million - $3.4 Million	-62,577 Reduced 12.24%	448,729 $24.3 Million
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $2.74 Million - $3.27 Million	-56,523 Reduced 9.95%	511,306 $26.2 Million
Q3 2023 Nov 14, 2023	BUY	$57.89 - $64.73 $482,628 - $539,654	8,337 Added 1.49%	567,829 $33 Million
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $1.11 Million - $1.23 Million	17,369 Added 3.2%	559,492 $35.8 Million
Q1 2023 May 15, 2023	BUY	$65.71 - $74.53 $1.78 Million - $2.01 Million	27,024 Added 5.25%	542,123 $37.6 Million
Q4 2022 Feb 15, 2023	BUY	$68.48 - $81.09 $1.16 Million - $1.37 Million	16,888 Added 3.39%	515,099 $37.1 Million
Q3 2022 Nov 16, 2022	BUY	$0.13 - $76.84 $15,159 - $8.96 Million	116,613 Added 30.56%	498,211 $35.4 Million
Q2 2022 Aug 23, 2022	SELL	$72.62 - $79.98 $2.24 Million - $2.47 Million	-30,910 Reduced 7.49%	381,598 $29.6 Million
Q2 2022 Aug 16, 2022	BUY	$72.62 - $79.98 $5.7 Million - $6.28 Million	78,552 Added 23.52%	412,508 $31.8 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $1.78 Million - $2.13 Million	28,924 Added 9.48%	333,956 $24.6 Million
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $1.38 Million - $1.6 Million	25,663 Added 9.19%	305,032 $19 Million
Q3 2021 Nov 16, 2021	BUY	$59.17 - $69.31 $2.54 Million - $2.97 Million	42,855 Added 18.12%	279,369 $16.7 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $306,392 - $333,661	-4,949 Reduced 2.05%	236,514 $15.8 Million
Q1 2021 May 17, 2021	BUY	$59.34 - $66.74 $392,593 - $441,551	6,616 Added 2.82%	241,463 $15.4 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $115,595 - $130,990	2,002 Added 0.86%	234,847 $14.7 Million
Q3 2020 Nov 17, 2020	BUY	$57.43 - $63.64 $380,760 - $421,933	6,630 Added 2.93%	232,845 $14 Million
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $1.15 Million - $1.35 Million	21,052 Added 10.26%	226,215 $13.4 Million
Q1 2020 May 15, 2020	BUY	$46.4 - $67.43 $584,129 - $848,876	12,589 Added 6.54%	205,163 $11.2 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $5.39 Million - $7.03 Million	109,531 Added 131.9%	192,574 $12.2 Million
Q3 2019 Nov 14, 2019	BUY	$42.77 - $50.71 $40,503 - $48,022	947 Added 1.15%	83,043 $4.21 Million
Q2 2019 Aug 13, 2019	BUY	$44.62 - $49.34 $266,604 - $294,806	5,975 Added 7.85%	82,096 $3.72 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $130,035 - $155,051	2,882 Added 3.94%	76,121 $3.63 Million
Q4 2018 Feb 13, 2019	SELL	$48.76 - $63.23 $138,429 - $179,509	-2,839 Reduced 3.73%	73,239 $3.81 Million
Q3 2018 Nov 15, 2018	BUY	$55.19 - $62.25 $1.84 Million - $2.08 Million	33,340 Added 78.01%	76,078 $4.72 Million
Q2 2018 Aug 13, 2018	BUY	$50.53 - $62.98 $544,612 - $678,798	10,778 Added 33.72%	42,738 $2.37 Million
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $592,788 - $682,419	-9,893 Reduced 23.64%	31,960 $1.98 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $2.36 Million - $2.58 Million	39,423 Added 1622.35%	41,853 $2.57 Million
Q3 2017 Feb 16, 2018	BUY	$55.23 - $63.74 $134,208 - $154,888	2,430	2,430 $155,000

Others Institutions Holding BMY

# of Institutions

2,400

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $105B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.

Account

Captrust Financial Advisors Bristol Myers Squibb CO Transaction History